Datapoint: Ascendis Scores Approval for First Once-Weekly Childhood GHD Drug

The FDA last week cleared Ascendis Pharma’s Skytrofa, a long-acting growth hormone, for the treatment of growth hormone deficiency (GHD) in patients weighing at least 25.4 pounds. Skytrofa is Acendis’ first FDA-approved drug, and is also the first once-weekly childhood GHD treatment. Novo Nordisk’s Norditropin is one of the most advantaged GHD therapies, holding preferred status under the pharmacy benefit for 12.8% of all covered lives, and growing to 45.0% with utilization management restrictions applied. Pfizer is also working on a once-weekly childhood GHD drug, with an FDA decision set for October.

SOURCE: MMIT Analytics, as of 8/30/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today